Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 4:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1297–1320 of 4,807 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Sensitivity Clear all
Completed Phase 3 Interventional Results available

Childhood Asthma Research and Education (CARE) Network Trial - Best Add-On Therapy Giving Effective Response (BADGER)

NCT00395304
View directory record Official record
Conditions
Asthma
Interventions
fluticasone propionate + montelukast, fluticasone propionate, fluticasone propionate + salmeterol
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
6 Years to 18 Years
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
5
States / cities
Tucson, Arizona • San Diego, California • Denver, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Oct 27, 2026, 4:44 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Polymerase Chain Reaction (PCR) Analysis of Nasal Polyps for Fungal DNA

NCT00739921
View directory record Official record
Conditions
Sinusitis, Nasal Polyps
Interventions
Nasal swab under endoscopic guidance
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2015
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 4, 2019 · Synced Oct 27, 2026, 4:44 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Bariatric and Obstructive Lung Disease Study II

NCT01127399
View directory record Official record
Conditions
Obesity, Asthma
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Oct 27, 2026, 4:44 PM EDT
Completed No phase listed Observational

Characterization of the Variability Of Insulin Secretory Parameters in the Meal Tolerance and the Maximal Stimulation Tests of Subjects With Prediabetes

NCT01663207
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Not listed
Lead sponsor
Foundation for the National Institutes of Health
Other
Eligibility
30 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2014 · Synced Oct 27, 2026, 4:44 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Efficacy and Safety of Benralizumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe Asthma

NCT03557307
View directory record Official record
Conditions
Asthma
Interventions
Benralizumab
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
598 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
23
States / cities
Flagstaff, Arizona • Los Angeles, California • Aurora, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2023 · Synced Oct 27, 2026, 4:44 PM EDT
Completed Phase 2 Interventional Results available

Efficacy And Safety Of GW642444M Comparing Placebo In Adolescent And Adult Subjects With Persistent Asthma.

NCT00600171
View directory record Official record
Conditions
Asthma
Interventions
GW642444M, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
30
States / cities
Phoenix, Arizona • Fresno, California • Huntington Beach, California + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Oct 27, 2026, 4:44 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies

NCT05794906
View directory record Official record
Conditions
Biochemically Recurrent Prostate Cancer
Interventions
Darolutamide (BAY1841788, Nubeqa), Placebo matching darolutamide, ADT
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
985 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
25
States / cities
Phoenix, Arizona • Duarte, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 27, 2026, 4:44 PM EDT
Terminated No phase listed Observational

Genetic Susceptibility and Risk of Second Cancers in Patients Who Have Undergone Stem Cell Transplant for Cancer

NCT00949052
View directory record Official record
Conditions
Cancer
Interventions
DNA analysis, polymorphism analysis, laboratory biomarker analysis, medical chart review, questionnaire administration, assessment of therapy complications, evaluation of cancer risk factors
Genetic · Other · Procedure
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Oct 27, 2026, 4:44 PM EDT
Terminated Phase 2 Interventional Results available

Study of ATI-450 in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS)

NCT04524858
View directory record Official record
Conditions
Cryopyrin-Associated Periodic Syndrome
Interventions
ATI-450
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
San Diego, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 27, 2026, 4:44 PM EDT
Completed Not applicable Interventional

Evaluating the Effectiveness of a Handbook for Parents of Children Newly Diagnosed With Food Allergy

NCT01914978
View directory record Official record
Conditions
Hypersensitivity, Food
Interventions
Food allergy handbook for parents, Food allergy treatment as usual
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 29, 2015 · Synced Oct 27, 2026, 4:44 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1)

NCT04146363
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Lebrikizumab, Placebo
Biological · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years and older
Enrollment
424 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
30
States / cities
Fort Smith, Arkansas • Beverly Hills, California • Encinitas, California + 26 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2022 · Synced Oct 27, 2026, 4:44 PM EDT
Completed Phase 4 Interventional Results available

The Study of Soy Isoflavones in Asthma

NCT01052116
View directory record Official record
Conditions
Asthma
Interventions
Soy isoflavone supplement, Placebo
Drug
Lead sponsor
American Lung Association Asthma Clinical Research Centers
Other
Eligibility
12 Years and older
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
18
States / cities
Tucson, Arizona • San Diego, California • Denver, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2016 · Synced Oct 27, 2026, 4:44 PM EDT
Withdrawn Phase 2 Interventional

Repeated High-dose Inhaled Corticosteroids for Asthma

NCT00695604
View directory record Official record
Conditions
Asthma
Interventions
Placebo, Fluticasone
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 8, 2018 · Synced Oct 27, 2026, 4:44 PM EDT
Terminated Phase 2 Interventional Results available

A Trial to Evaluate the Efficacy and Safety of Different Doses of KVD824 for Prophylactic Treatment of HAE Type I or II

NCT05055258
View directory record Official record
Conditions
Angioedema, Hereditary, Types I and II
Interventions
KVD824, Placebo to KVD824
Drug
Lead sponsor
KalVista Pharmaceuticals, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
13
States / cities
Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 27, 2026, 4:44 PM EDT
Completed Phase 2 Interventional Results available

To Assess the Efficacy and Safety of SCD-044 in the Treatment of Moderate to Severe Atopic Dermatitis

NCT04684485
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Placebo, SCD-044_Dose 1, SCD-044_Dose 2, SCD-044_Dose 3
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
34
States / cities
Phoenix, Arizona • Yuma, Arizona • Encino, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Oct 27, 2026, 4:44 PM EDT
Terminated Phase 2 Interventional Results available

Study Evaluating the Safety and Effects of MN-221 in Subjects Experiencing an Acute Exacerbation of Asthma

NCT00683449
View directory record Official record
Conditions
Asthma, Status Asthmaticus
Interventions
Dose Group 1, MN-221 placebo, Dose Group 2, Dose Group 3
Drug
Lead sponsor
MediciNova
Industry
Eligibility
18 Years to 55 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
9
States / cities
Phoenix, Arizona • Los Angeles, California • Sylmar, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2011 · Synced Oct 27, 2026, 4:44 PM EDT
Completed Phase 3 Interventional Results available

Albuterol HFA MDI in Pediatric Participants With Asthma

NCT00577655
View directory record Official record
Conditions
Asthma
Interventions
Albuterol, Placebo, Proventil® HFA
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
4 Years to 11 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
13
States / cities
Huntington Beach, California • Palmdale, California • Paramount, California + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2021 · Synced Oct 27, 2026, 4:44 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis

NCT00243685
View directory record Official record
Conditions
Breast Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Sarcoma, Soft Tissue
Interventions
Laboratory Assay, Mick Assay
Other
Lead sponsor
Pierian Biosciences
Industry
Eligibility
18 Years to 85 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
3
States / cities
Nashville, Tennessee • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 26, 2012 · Synced Oct 27, 2026, 4:44 PM EDT
Completed Phase 2 Interventional

Dose Response Study of Levalbuterol in the Prevention of Exercise Induced Bronchoconstriction Compared to Racemic Albuterol in Pediatric Subjects

NCT00685347
View directory record Official record
Conditions
Asthma, Bronchoconstriction
Interventions
Levalbuterol HFA MDI, Racemic Albuterol
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
6 Years to 11 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
6
States / cities
Long Beach, California • Denver, Colorado • Englewood, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Oct 27, 2026, 4:44 PM EDT
Completed Not applicable Interventional Results available

Effect of Pimecrolimus Cream on Cathelicidin Levels in Subjects With Eczema

NCT00946478
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Pimecrolimus, Vehicle cream
Drug · Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Mar 10, 2014 · Synced Oct 27, 2026, 4:44 PM EDT
Completed Early Phase 1 Interventional

A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors

NCT06273852
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Soft Tissue Sarcoma Adult, Triple Negative Breast Cancer
Interventions
PBA-0405
Drug
Lead sponsor
Pure Biologics S.A.
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
Shreveport, Louisiana • Portland, Oregon • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Oct 27, 2026, 4:44 PM EDT
Terminated Phase 2 Interventional Results available

Vitamin D to Prevent Severe Asthma Exacerbations (Vit-D-Kids Asthma)

NCT02687815
View directory record Official record
Conditions
Asthma
Interventions
vitamin D3 4000 IU, Placebo
Drug
Lead sponsor
Juan Celedon, MD
Other
Eligibility
6 Years to 16 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
7
States / cities
San Francisco, California • Denver, Colorado • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2021 · Synced Oct 27, 2026, 4:44 PM EDT
Completed Phase 3 Interventional Results available

A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor

NCT04444895
View directory record Official record
Conditions
Angioedema
Interventions
Lanadelumab
Drug
Lead sponsor
Shire
Industry
Eligibility
12 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
15
States / cities
Birmingham, Alabama • Scottsdale, Arizona • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2024 · Synced Oct 27, 2026, 4:44 PM EDT
Terminated Phase 2 Interventional

Capecitabine in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cavity Cancer

NCT00006812
View directory record Official record
Conditions
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
capecitabine
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
30
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2013 · Synced Oct 27, 2026, 4:44 PM EDT